Zuellig Pharma Acquires Cialis Rights to Improve Healthcare Access in Singapore
Zuellig Pharma, a major healthcare services provider, has announced that it has acquired the rights to the medication Cialis® (tadalafil) from the pharmaceutical company Lilly. This agreement covers Singapore and several other markets across Asia.
Cialis is a well-known medication primarily used to treat erectile dysfunction (ED) and benign prostatic hyperplasia (BPH), a condition that causes an enlarged prostate. By taking over the ownership and distribution of this drug, Zuellig Pharma aims to strengthen its portfolio of men’s health products in the region.
The company stated that this acquisition is part of a broader strategy to increase the availability of essential medicines. By managing the supply chain more directly, Zuellig Pharma hopes to ensure that patients in Singapore and across Asia have more reliable access to this treatment.
For patients in Singapore, this change means that the distribution and management of Cialis will now be handled by Zuellig Pharma. The company plans to work closely with local healthcare providers to maintain a steady supply of the medication for those who need it.
This move reflects a growing trend in the pharmaceutical industry, where regional companies are taking on more responsibility for the distribution of established global brands. Zuellig Pharma expects that this partnership will help improve health outcomes for men suffering from these specific conditions.